Shota Omori Selected Research

Shota Omori Research Topics

Disease

43	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2023 - 08/2015
26	Neoplasms (Cancer) 01/2023 - 08/2015
8	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 03/2023 - 04/2018
7	Lung Neoplasms (Lung Cancer) 09/2022 - 06/2017
6	Neoplasm Metastasis (Metastasis) 12/2021 - 04/2018
4	Pneumonia (Pneumonitis) 04/2022 - 10/2020
4	Cachexia 01/2022 - 11/2017
4	Interstitial Lung Diseases (Interstitial Lung Disease) 03/2021 - 01/2018
2	Carcinoma (Carcinomatosis) 01/2024 - 05/2017
2	Organizing Pneumonia 12/2023 - 03/2016
2	Radiation Pneumonitis 03/2023 - 03/2021
2	Inflammation (Inflammations) 01/2022 - 01/2019
2	Melanoma (Melanoma, Malignant) 01/2020 - 03/2016
2	Neutropenia 11/2017 - 06/2017
1	Lung Injury 12/2023
1	Disease Progression 01/2023
1	Weight Loss (Weight Reduction) 02/2022
1	Hemorrhage 01/2022
1	Hypertension (High Blood Pressure) 01/2022
1	Pulmonary Embolism 01/2021
1	Brain Neoplasms (Brain Tumor) 01/2019
1	Malnutrition (Nutritional Deficiencies) 01/2019
1	Cardiomyopathies (Cardiomyopathy) 10/2018
1	Adenocarcinoma of Lung 02/2018
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/2018
1	Vomiting 09/2017
1	Sleepiness 09/2017
1	Nausea 09/2017
1	Febrile Neutropenia 06/2017

Drug/Important Bio-Agent (IBA)

13	ErbB Receptors (EGF Receptor)IBA 03/2022 - 08/2015
10	Tyrosine Kinase InhibitorsIBA 03/2022 - 07/2016
8	Immune Checkpoint InhibitorsIBA 01/2023 - 01/2020
7	B7-H1 AntigenIBA 08/2022 - 12/2018
6	durvalumabIBA 04/2022 - 10/2020
6	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 11/2016
4	Carboplatin (JM8)FDA LinkGeneric 03/2022 - 06/2017
4	NivolumabIBA 03/2022 - 03/2016
4	PlatinumIBA 11/2019 - 06/2017
3	pembrolizumabIBA 01/2022 - 05/2020
3	osimertinibIBA 11/2021 - 01/2020
3	Gefitinib (Iressa)FDA Link 01/2020 - 08/2015
2	LigandsIBA 01/2023 - 04/2021
2	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2019
2	Pemetrexed (MTA)FDA Link 03/2022 - 11/2016
2	130-nm albumin-bound paclitaxelIBA 01/2022 - 04/2021
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2022 - 11/2019
2	Angiogenesis InhibitorsIBA 01/2022 - 11/2021
2	Biomarkers (Surrogate Marker)IBA 04/2021 - 12/2018
2	Etoposide (VP 16)FDA LinkGeneric 11/2019 - 06/2017
2	amrubicinIBA 11/2019 - 05/2017
1	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2023
1	CrizotinibIBA 12/2023
1	entrectinibIBA 12/2023
1	Immune Checkpoint ProteinsIBA 01/2023
1	Surface Antigens (Surface Antigen)IBA 09/2022
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2022
1	RamucirumabIBA 01/2022
1	Therapeutic UsesIBA 01/2022
1	fibrin fragment D (D-dimer)IBA 01/2021
1	AnticoagulantsIBA 01/2021
1	alectinibIBA 01/2019
1	Anaplastic Lymphoma KinaseIBA 01/2019
1	Indicators and Reagents (Reagents)IBA 01/2019
1	antigen CYFRA21.1IBA 02/2018
1	AlbuminsIBA 11/2017
1	Glycoproteins (Glycoprotein)IBA 11/2017
1	Blood Proteins (Serum Proteins)IBA 11/2017
1	AcidsIBA 11/2017
1	Docetaxel (Taxotere)FDA Link 11/2017
1	Vinorelbine (Navelbine)FDA LinkGeneric 09/2017
1	Palonosetron (Aloxi)FDA Link 09/2017
1	Olanzapine (Zyprexa)FDA Link 09/2017
1	AntiemeticsIBA 09/2017
1	Aprepitant (Emend)FDA Link 09/2017
1	Dexamethasone (Maxidex)FDA LinkGeneric 09/2017
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 06/2017
1	Bevacizumab (Avastin)FDA Link 11/2016

Therapy/Procedure

21	Drug Therapy (Chemotherapy) 01/2024 - 11/2016
18	Therapeutics 03/2023 - 11/2016
9	Chemoradiotherapy 01/2022 - 01/2018
8	Radiotherapy 03/2023 - 06/2017
3	Immunotherapy 01/2022 - 01/2021
3	Aftercare (After-Treatment) 11/2021 - 10/2020
2	Activities of Daily Living (ADL) 04/2021 - 11/2017
1	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 06/2022
1	Combination Drug Therapy (Combination Chemotherapy) 01/2019
1	Cranial Irradiation 04/2018
1	Length of Stay 11/2017
1	Adjuvant Chemotherapy 09/2017